A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

NCT01059318 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphangioleiomyomatosis

Interventions

DRUG: Everolimus

Sponsor

Novartis Pharmaceuticals